Allarity Therapeutics, Inc. ALLR

Overview

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company that specializes in the field of oncology therapeutics. The company is renowned for its innovative approach to cancer treatment, utilizing drug-specific companion diagnostics produced through its proprietary drug response predictor technology. Founded in 2004 and based in Boston, Massachusetts, Allarity Therapeutics is at the forefront of developing personalized treatment options for cancer patients, aiming to enhance the efficacy and reduce the side effects of cancer therapies. Its collaboration with Detsamma Investments Pty. Ltd. for the development of Deflexifol for solid tumors highlights the company's commitment to expanding its pipeline and improving outcomes for patients facing challenging diagnoses.

Products and Services

• Stenoparib

A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Stenoparib's mechanism of action targets the repair processes of damaged DNA, thereby inhibiting cancer cell growth and proliferation.

• Dovitinib

A pan-tyrosine kinase inhibitor being developed for the treatment of renal cell carcinoma. This therapeutic candidate disrupts multiple tyrosine kinase pathways involved in tumor growth and angiogenesis, offering a broad-based approach to cancer therapy.

• IXEMPRA (ixabepilone)

A selective microtubule inhibitor in Phase 2 clinical trials for metastatic breast cancer. IXEMPRA works by stabilizing microtubules, which are vital for cell division, leading to the death of rapidly dividing cancer cells.

• LiPlaCis

A liposomal formulation of cisplatin that is in Phase 2 clinical trials for patients with metastatic breast cancer. LiPlaCis aims to enhance the delivery and efficacy of cisplatin, a chemotherapy drug, by encapsulating it in liposomes to target cancer cells more effectively while minimizing side effects.

• 2X-111

A liposomal formulation of doxorubicin that is undergoing Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Like LiPlaCis, 2X-111 aims to improve the therapeutic index of doxorubicin, a widely used anticancer agent, through targeted delivery.